Association of Beta-2 Microglobulin Concentrations with Frailty in Patients Undergoing Chronic Hemodialysis
Open Access
- 1 June 2025
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 18, 151-162
Abstract
Introduction: Patients with Chronic Kidney Disease (CKD) undergoing regular hemodialysis experience various metabolic changes, including premature aging marked by increased prevalence of frailty. Beta-2 microglobulin (B2M), a uremic toxin whose concentration significantly increases in hemodialysis patients, has emerged as a potential biomarker of frailty. Previous evidence suggests potential link between B2M and frailty in older adults. However, data on its relationship with frailty in hemodialysis patients remains limited. Purpose: To determine the relationship between B2M concentration and frailty in hemodialysis patients. Patients and Methods: This is a cross-sectional study utilizing primary data from hemodialysis patients at Rumah Sakit Cipto Mangunkusumo (RSCM), employing a total sampling method. Beta-2 microglobulin was measured using the Enzyme-Linked Fluorescent Assay (ELFA) method. Frailty was assessed using the Frailty Index 40-item. Medical history was obtained from medical records and interviews. Chi-square tests were performed to determine the relationship between B2M and frailty. Multivariate analysis was conducted to determine variables that affect frailty. Results: A total of 79 subjects participated in the study. The median B2M concentration was 32.8 (IQR 29.8– 36.77). Higher B2M concentration showed a trend toward increased frailty prevalence (PR of 4.83, 95% CI 0.69– 33.81, p = 0.113). The final multivariate analysis showed that sarcopenia (PR 5.37; 95% CI 2.88– 10.04) was strongly and consistently associated with frailty prevalence. Conclusion: Higher B2M showed a trend towards increased frailty prevalence; however, this association is not statistically significant. Sarcopenia is a significant factor influencing the prevalence of frailty in hemodialysis patients.Keywords
This publication has 29 references indexed in Scilit:
- Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns StudyClinical Kidney Journal, 2020
- A roadmap to build a phenotypic metric of ageing: insights from the Baltimore Longitudinal Study of AgingJournal of Internal Medicine, 2020
- Chronic Kidney DiseaseThe Lancet, 2017
- Association Between Serum β 2 ‐Microglobulin Levels and Prevalent and Incident Physical Frailty in Community‐Dwelling Older WomenJournal of the American Geriatrics Society, 2017
- Frailty measurement in research and clinical practice: A reviewEuropean Journal of Internal Medicine, 2016
- Biomarkers for physical frailty and sarcopenia: state of the science and future developmentsJournal of Cachexia, Sarcopenia and Muscle, 2015
- JapaneseSociety forDialysisTherapyClinicalGuideline for “Maintenance Hemodialysis: Hemodialysis Prescriptions”Therapeutic Apheresis and Dialysis, 2015
- Plasma Beta-2 Microglobulin as a Marker of Frailty in Older Adults: A Pilot StudyThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2011
- Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre studyNephrology Dialysis Transplantation, 2007
- Change from conventional haemodiafiltration to on-line haemodiafiltrationNephrology Dialysis Transplantation, 1999